MannKind | MNKD - Operating Expenses


MannKind reported $110.21M in Operating Expenses for its fiscal quarter ending in June of 2026.





Operating Expenses Change Date
Adma Biologics USD 64.2M 12.21M Mar/2026
BioCryst Pharmaceuticals USD 119.78M 673.63M Jun/2026
Eli Lilly USD 10.52B 496M Jun/2026
Halozyme Therapeutics USD 193.34M 1.15M Jun/2026
Insmed USD 526.79M 20.55M Jun/2026
Karyopharm Therapeutics USD 61.83M 9.9M Mar/2026
MacroGenics USD 42.87M 21.68M Jun/2026
MannKind USD 110.21M 690K Jun/2026
Merck USD 15.77B 2.4B Jun/2026
Minerva Neurosciences USD 4.52M 155.46K Dec/2024
Novavax USD 126.2M 23.62M Dec/2025
Novo Nordisk DKK 6.96B 30.25B Jun/2026
Pfizer USD 85.19B 4.91B Jun/2026
Sanofi EUR 9.92B 607M Jun/2026
Xencor USD 87.82M 5.44M Jun/2026